WO2024105635 - USES OF ZLN-005 AND RELATED COMPOUNDS
National phase entry:
Publication Number
WO/2024/105635
Publication Date
23.05.2024
International Application No.
PCT/IB2023/061651
International Filing Date
17.11.2023
Title **
[English]
USES OF ZLN-005 AND RELATED COMPOUNDS
[French]
UTILISATIONS DE ZLN-005 ET COMPOSÉS ASSOCIÉS
Applicants **
GOJO, Satoshi
Inventors
GOJO, Satoshi
Priority Data
63/426,426
18.11.2022
US
63/482,384
31.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3566 | |
| EPO | Filing, Examination, Granting | 19776 | |
| Japan | Filing, Examination, Granting | 3243 | |
| South Korea | Filing, Examination, Granting | 4091 | |
| USA | Filing, Examination, Granting | 10990 |
Total:
41,666
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Methods of treating diseases and disorders associated with impaired lysosomal acidification, methods for increasing lysosomal acidity, and methods of treating sepsis, infection, and diseases and disorders associated with V-ATPase dysfunction with ZLN-005 and other compounds of Formula (I), and salts, hydrates, deuterated analogs, and fluorinated analogs thereof.[French]
Des procédés de traitement de maladies et de troubles associés à une acidification lysosomale altérée, des procédés d'augmentation de l'acidité lysosomale, et des procédés de traitement de la sepsie, d'une infection et de maladies et de troubles associés à un dysfonctionnement de la V-ATPase avec ZLN-005 et d'autres composés de formule (I), et des sels, des hydrates, des analogues deutérés et des analogues fluorés de ceux-ci.